A Phase 1/2 Trial of ADI-270 in ccRCC

Summary

This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

Timeline

Start

2024-12-12

Primary completion

2026-06

Completion

2027-06

Publications

• Nishimoto KP, Lamture G, Chanthery Y, Teague AG, Verma Y, Au M, Smith-Boeck M, Salum M, Murthy P, Gundurao SRY, Kaur R, Zhang J, Azameera A, Wong JTS, Speltz EB, Wang KM, Doan A, Sethuraman J, Bhatwala D, Giner-Rubio A, Puligujja P, Budworth H, Rold CJ, Panuganti S, Jakobovits A, Herrman M, Bhat A, Green S, Aftab BT. ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies. J Immunother Cancer. 2025 Jul 1;13(7):e011704. doi: 10.1136/jitc-2025-011704.

Drugs

Indications